蛋白酶3在慢性阻塞性肺疾病中的研究進展_Chinese Journal of Respiratory and Critical Care Medicine

Authors：

王鳳燕 ¹ , 梁振宇 ¹ , 李雪萍 ¹ ,  陳榮昌 ^1,2

1. ;
2. ;

Corresponding?author：

陳榮昌, Email: chenrc@vip.163.com

Keywords：

DOI：

10.7507/1671-6205.202307038

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Citation： 王鳳燕, 梁振宇, 李雪萍, 陳榮昌. 蛋白酶3在慢性阻塞性肺疾病中的研究進展. Chinese Journal of Respiratory and Critical Care Medicine, 2023, 22(11): 832-836. doi: 10.7507/1671-6205.202307038 Copy

1.	GBD 2017 DALYs and HALE Collaborators. Global, regional, and national disability-adjusted life-years (DALYs) for 359 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet, 2018, 392(10159): 1859-1922.
2.	中華醫學會呼吸病學分會慢性阻塞性肺疾病學組, 中國醫師協會呼吸醫師分會慢性阻塞性肺疾病工作委員會. 慢性阻塞性肺疾病診治指南(2021年修訂版). 中華結核和呼吸雜志, 2021, 44: 170-205.
3.	Crisford H, Sapey E, Stockley RA. Proteinase 3: a potential target in chronic obstructive pulmonary disease and other chronic inflammatory diseases. Respir Res, 2018, 19(1): 180.
4.	Sinden NJ, Stockley RA. Proteinase 3 activity in sputum from subjects with alpha-1-antitrypsin deficiency and COPD. Eur Respir J, 2013, 41(5): 1042-1050.
5.	Witko-Sarsat V, Cramer EM, Hieblot C, et al. Presence of proteinase 3 in secretory vesicles: evidence of a novel, highly mobilizable intracellular pool distinct from azurophil granules. Blood, 1999, 94(7): 2487-2496.
6.	Korkmaz B, Jaillet J, Jourdan ML, et al. Catalytic activity and inhibition of wegener antigen proteinase 3 on the cell surface of human polymorphonuclear neutrophils. J Biol Chem, 2009, 284(30): 19896-19902.
7.	Ohbayashi H. Neutrophil elastase inhibitors as treatment for COPD. Expert Opin Investig Drugs, 2002, 11(7): 965-980.
8.	Korkmaz B, Attucci S, Juliano MA, et al. Measuring elastase, proteinase 3 and cathepsin G activities at the surface of human neutrophils with fluorescence resonance energy transfer substrates. Nat Protoc, 2008, 3(6): 991-1000.
9.	Campbell EJ, Campbell MA, Owen CA. Bioactive proteinase 3 on the cell surface of human neutrophils: quantification, catalytic activity, and susceptibility to inhibition. J Immunol, 2000, 165(6): 3366-3374.
10.	Korkmaz B, Poutrain P, Hazouard E, et al. Competition between elastase and related proteases from human neutrophil for binding to alpha1-protease inhibitor. Am J Respir Cell Mol Biol, 2005, 32(6): 553-559.
11.	Sinden N J, Baker M J, Smith DJ, et al. α-1-antitrypsin variants and the proteinase/antiproteinase imbalance in chronic obstructive pulmonary disease. Am J Physiol Lung Cell Mol Physiol, 2015, 308(2): L179-L190.
12.	Jerke U, Hernandez DP, Beaudette P, et al. Neutrophil serine proteases exert proteolytic activity on endothelial cells. Kidney Int, 2015, 88(4): 764-775.
13.	Korkmaz B, Lesner A, Guarino C, et al. Inhibitors and antibody fragments as potential anti-inflammatory therapeutics targeting neutrophil proteinase 3 in human disease. Pharmacol Rev, 2016, 68(3): 603-630.
14.	Pendergraft WR, Rudolph EH, Falk RJ, et al. Proteinase 3 sidesteps caspases and cleaves p21(Waf1/Cip1/Sdi1) to induce endothelial cell apoptosis. Kidney Int, 2004, 65(1): 75-84.
15.	Kessenbrock K, Fr?hlich L, Sixt M, et al. Proteinase 3 and neutrophil elastase enhance inflammation in mice by inactivating antiinflammatory progranulin. J Clin Invest, 2008, 118(7): 2438-2447.
16.	Newby PR, Crossley D, Crisford H, et al. A specific proteinase 3 activity footprint in α(1)-antitrypsin deficiency. ERJ Open Res, 2019, 5(3): 00095-2019.
17.	Gudmann NS, Manon-Jensen T, Sand J, et al. Lung tissue destruction by proteinase 3 and cathepsin G mediated elastin degradation is elevated in chronic obstructive pulmonary disease. Biochem Biophys Res Commun, 2018, 503(3): 1284-1290.
18.	Korkmaz B, Jenne DE, Gauthier F. Relevance of the mouse model as a therapeutic approach for neutrophil proteinase 3-associated human diseases. Int Immunopharmacol, 2013, 17(4): 1198-1205.
19.	Polosukhin VV, Gutor SS, Du RH, et al. Small airway determinants of airflow limitation in chronic obstructive pulmonary disease. Thorax, 2021, 76(11): 1079-1088.
20.	Dicker AJ, Huang J, Lonergan M, et al. The sputum microbiome, airway inflammation, and mortality in chronic obstructive pulmonary disease. J Allergy Clin Immunol, 2021, 147(1): 158-167.
21.	李四香, 趙爽, 李為民. 中性粒細胞與淋巴細胞比值在慢性阻塞性肺疾病中的應用研究進展. 中國呼吸與危重監護雜志, 2020, 19(3): 304-308.
22.	Sapey E, Stockley JA, Greenwood H, et al. Behavioral and structural differences in migrating peripheral neutrophils from patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med, 2011, 183(9): 1176-1186.
23.	Jasper AE, McIver WJ, Sapey E, et al. Understanding the role of neutrophils in chronic inflammatory airway disease. F1000Res, 2019, 8: F1000 Faculty Rev-557.
24.	Crisford H, Newby PR, Sapey E, et al. S15 Proteinase 3 activity in PiSZ alpha-1 antitrypsin deficiency and non-deficient chronic obstructive pulmonary disease. Thorax, 2018, Suppl 4(73): A10.
25.	Beeh KM, Kornmann O, Buhl R, et al. Neutrophil chemotactic activity of sputum from patients with COPD: role of interleukin 8 and leukotriene B4. Chest, 2003, 123(4): 1240-1247.
26.	Moldoveanu B, Otmishi P, Jani P, et al. Inflammatory mechanisms in the lung. J Inflamm Res, 2009, 2: 1-11.
27.	Hiemstra PS, Wetering S, Stolk. Neutrophil serine proteinases and defensins in chronic obstructive pulmonary disease: effects on pulmonary epithelium. Eur Respir J, 1998, 12(5): 1200-1208.
28.	Bank U, Ansorge S. More than destructive: neutrophil-derived serine proteases in cytokine bioactivity control. J Leukoc Biol, 2001, 69(2): 197-206.
29.	Pederzoli-Ribeil M, Maione F, Cooper D, et al. Design and characterization of a cleavage-resistant Annexin A1 mutant to control inflammation in the microvasculature. Blood, 2010, 116(20): 4288-4296.
30.	Richens TR, Linderman DJ, Horstmann SA, et al. Cigarette smoke impairs clearance of apoptotic cells through oxidant-dependent activation of RhoA. Am J Respir Crit Care Med, 2009, 179(11): 1011-1021.
31.	Thieblemont N, Witko-Sarsat V, Ariel A. Regulation of macrophage activation by proteins expressed on apoptotic neutrophils: subversion towards autoimmunity by proteinase 3. Eur J Clin Invest, 2018, 48 Suppl 2: e12990.
32.	Loison F, Zhu H, Karatepe K, et al. Proteinase 3-dependent caspase-3 cleavage modulates neutrophil death and inflammation. J Clin Invest, 2014, 124(10): 4445-4458.
33.	Korkmaz B, Horwitz MS, Jenne DE, et al. Neutrophil elastase, proteinase 3, and cathepsin G as therapeutic targets in human diseases. Pharmacol Rev, 2010, 62(4): 726-759.
34.	Stockley RA. Neutrophils and protease/antiprotease imbalance. Am J Respir Crit Care Med, 1999, 160(5 Pt 2): S49-S52.
35.	Guyot N, Wartelle J, Malleret L, et al. Unopposed cathepsin G, neutrophil elastase, and proteinase 3 cause severe lung damage and emphysema. Am J Pathol, 2014, 184(8): 2197-2210.
36.	Caramori G, Ruggeri P, Di Stefano A, et al. Autoimmunity and COPD: Clinical Implications. Chest, 2018, 153(6): 1424-1431.
37.	Zhou JS, Li ZY, Xu XC, et al. Cigarette smoke-initiated autoimmunity facilitates sensitisation to elastin-induced COPD-like pathologies in mice. Eur Respir J, 2020, 56(3): 2000404.
38.	Liang Z, Wang F, Zhang D, et al. Sputum and serum autoantibody profiles and their clinical correlation patterns in COPD patients with and without eosinophilic airway inflammation. J Thorac Dis, 2020, 12(6): 3085-3100.
39.	Costa S, Bevilacqua D, Cassatella M A, et al. Recent advances on the crosstalk between neutrophils and B or T lymphocytes. Immunology, 2019, 156(1): 23-32.
40.	Martin KR, Pederzoli-Ribeil M, Pacreau E, et al. Transgenic mice expressing human proteinase 3 exhibit sustained neutrophil-associated peritonitis. J Immunol, 2017, 199(11): 3914-3924.
41.	Wang F, Liang Z, Yang Y, et al. Sputum IgA autoantibodies predict the chronic obstructive pulmonary disease exacerbations. Am J Respir Crit Care Med, 2019(199): A4048.
42.	Liang Z, Long F, Deng K, et al. Dissociation between airway and systemic autoantibody responses in chronic obstructive pulmonary disease. Ann Transl Med, 2020, 8(15): 918.
43.	Stockley RA. Alpha-1 Antitrypsin Deficiency: Have we got the right proteinase? Chronic Obstr Pulm Dis, 2020, 7(3): 163-171.
44.	Viglio S, Bak E G, Schouten I, et al. Protease-specific biomarkers to analyse protease inhibitors for emphysema associated with alpha 1-antitrypsin deficiency. An Overview of Current Approaches. Int J Mol Sci, 2021, 22(3): 1065.
45.	Watz H, Nagelschmitz J, Kirsten A, et al. Safety and efficacy of the human neutrophil elastase inhibitor BAY 85-8501 for the treatment of non-cystic fibrosis bronchiectasis: a randomized controlled trial. Pulm Pharmacol Ther, 2019, 56: 86-93.
46.	Griese M, Kappler M, Gaggar A, et al. Inhibition of airway proteases in cystic fibrosis lung disease. Eur Respir J, 2008, 32(3): 783-795.

1. GBD 2017 DALYs and HALE Collaborators. Global, regional, and national disability-adjusted life-years (DALYs) for 359 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet, 2018, 392(10159): 1859-1922.
2. 中華醫學會呼吸病學分會慢性阻塞性肺疾病學組, 中國醫師協會呼吸醫師分會慢性阻塞性肺疾病工作委員會. 慢性阻塞性肺疾病診治指南(2021年修訂版). 中華結核和呼吸雜志, 2021, 44: 170-205.
3. Crisford H, Sapey E, Stockley RA. Proteinase 3: a potential target in chronic obstructive pulmonary disease and other chronic inflammatory diseases. Respir Res, 2018, 19(1): 180.
4. Sinden NJ, Stockley RA. Proteinase 3 activity in sputum from subjects with alpha-1-antitrypsin deficiency and COPD. Eur Respir J, 2013, 41(5): 1042-1050.
5. Witko-Sarsat V, Cramer EM, Hieblot C, et al. Presence of proteinase 3 in secretory vesicles: evidence of a novel, highly mobilizable intracellular pool distinct from azurophil granules. Blood, 1999, 94(7): 2487-2496.
6. Korkmaz B, Jaillet J, Jourdan ML, et al. Catalytic activity and inhibition of wegener antigen proteinase 3 on the cell surface of human polymorphonuclear neutrophils. J Biol Chem, 2009, 284(30): 19896-19902.
7. Ohbayashi H. Neutrophil elastase inhibitors as treatment for COPD. Expert Opin Investig Drugs, 2002, 11(7): 965-980.
8. Korkmaz B, Attucci S, Juliano MA, et al. Measuring elastase, proteinase 3 and cathepsin G activities at the surface of human neutrophils with fluorescence resonance energy transfer substrates. Nat Protoc, 2008, 3(6): 991-1000.
9. Campbell EJ, Campbell MA, Owen CA. Bioactive proteinase 3 on the cell surface of human neutrophils: quantification, catalytic activity, and susceptibility to inhibition. J Immunol, 2000, 165(6): 3366-3374.
10. Korkmaz B, Poutrain P, Hazouard E, et al. Competition between elastase and related proteases from human neutrophil for binding to alpha1-protease inhibitor. Am J Respir Cell Mol Biol, 2005, 32(6): 553-559.
11. Sinden N J, Baker M J, Smith DJ, et al. α-1-antitrypsin variants and the proteinase/antiproteinase imbalance in chronic obstructive pulmonary disease. Am J Physiol Lung Cell Mol Physiol, 2015, 308(2): L179-L190.
12. Jerke U, Hernandez DP, Beaudette P, et al. Neutrophil serine proteases exert proteolytic activity on endothelial cells. Kidney Int, 2015, 88(4): 764-775.
13. Korkmaz B, Lesner A, Guarino C, et al. Inhibitors and antibody fragments as potential anti-inflammatory therapeutics targeting neutrophil proteinase 3 in human disease. Pharmacol Rev, 2016, 68(3): 603-630.
14. Pendergraft WR, Rudolph EH, Falk RJ, et al. Proteinase 3 sidesteps caspases and cleaves p21(Waf1/Cip1/Sdi1) to induce endothelial cell apoptosis. Kidney Int, 2004, 65(1): 75-84.
15. Kessenbrock K, Fr?hlich L, Sixt M, et al. Proteinase 3 and neutrophil elastase enhance inflammation in mice by inactivating antiinflammatory progranulin. J Clin Invest, 2008, 118(7): 2438-2447.
16. Newby PR, Crossley D, Crisford H, et al. A specific proteinase 3 activity footprint in α(1)-antitrypsin deficiency. ERJ Open Res, 2019, 5(3): 00095-2019.
17. Gudmann NS, Manon-Jensen T, Sand J, et al. Lung tissue destruction by proteinase 3 and cathepsin G mediated elastin degradation is elevated in chronic obstructive pulmonary disease. Biochem Biophys Res Commun, 2018, 503(3): 1284-1290.
18. Korkmaz B, Jenne DE, Gauthier F. Relevance of the mouse model as a therapeutic approach for neutrophil proteinase 3-associated human diseases. Int Immunopharmacol, 2013, 17(4): 1198-1205.
19. Polosukhin VV, Gutor SS, Du RH, et al. Small airway determinants of airflow limitation in chronic obstructive pulmonary disease. Thorax, 2021, 76(11): 1079-1088.
20. Dicker AJ, Huang J, Lonergan M, et al. The sputum microbiome, airway inflammation, and mortality in chronic obstructive pulmonary disease. J Allergy Clin Immunol, 2021, 147(1): 158-167.
21. 李四香, 趙爽, 李為民. 中性粒細胞與淋巴細胞比值在慢性阻塞性肺疾病中的應用研究進展. 中國呼吸與危重監護雜志, 2020, 19(3): 304-308.
22. Sapey E, Stockley JA, Greenwood H, et al. Behavioral and structural differences in migrating peripheral neutrophils from patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med, 2011, 183(9): 1176-1186.
23. Jasper AE, McIver WJ, Sapey E, et al. Understanding the role of neutrophils in chronic inflammatory airway disease. F1000Res, 2019, 8: F1000 Faculty Rev-557.
24. Crisford H, Newby PR, Sapey E, et al. S15 Proteinase 3 activity in PiSZ alpha-1 antitrypsin deficiency and non-deficient chronic obstructive pulmonary disease. Thorax, 2018, Suppl 4(73): A10.
25. Beeh KM, Kornmann O, Buhl R, et al. Neutrophil chemotactic activity of sputum from patients with COPD: role of interleukin 8 and leukotriene B4. Chest, 2003, 123(4): 1240-1247.
26. Moldoveanu B, Otmishi P, Jani P, et al. Inflammatory mechanisms in the lung. J Inflamm Res, 2009, 2: 1-11.
27. Hiemstra PS, Wetering S, Stolk. Neutrophil serine proteinases and defensins in chronic obstructive pulmonary disease: effects on pulmonary epithelium. Eur Respir J, 1998, 12(5): 1200-1208.
28. Bank U, Ansorge S. More than destructive: neutrophil-derived serine proteases in cytokine bioactivity control. J Leukoc Biol, 2001, 69(2): 197-206.
29. Pederzoli-Ribeil M, Maione F, Cooper D, et al. Design and characterization of a cleavage-resistant Annexin A1 mutant to control inflammation in the microvasculature. Blood, 2010, 116(20): 4288-4296.
30. Richens TR, Linderman DJ, Horstmann SA, et al. Cigarette smoke impairs clearance of apoptotic cells through oxidant-dependent activation of RhoA. Am J Respir Crit Care Med, 2009, 179(11): 1011-1021.
31. Thieblemont N, Witko-Sarsat V, Ariel A. Regulation of macrophage activation by proteins expressed on apoptotic neutrophils: subversion towards autoimmunity by proteinase 3. Eur J Clin Invest, 2018, 48 Suppl 2: e12990.
32. Loison F, Zhu H, Karatepe K, et al. Proteinase 3-dependent caspase-3 cleavage modulates neutrophil death and inflammation. J Clin Invest, 2014, 124(10): 4445-4458.
33. Korkmaz B, Horwitz MS, Jenne DE, et al. Neutrophil elastase, proteinase 3, and cathepsin G as therapeutic targets in human diseases. Pharmacol Rev, 2010, 62(4): 726-759.
34. Stockley RA. Neutrophils and protease/antiprotease imbalance. Am J Respir Crit Care Med, 1999, 160(5 Pt 2): S49-S52.
35. Guyot N, Wartelle J, Malleret L, et al. Unopposed cathepsin G, neutrophil elastase, and proteinase 3 cause severe lung damage and emphysema. Am J Pathol, 2014, 184(8): 2197-2210.
36. Caramori G, Ruggeri P, Di Stefano A, et al. Autoimmunity and COPD: Clinical Implications. Chest, 2018, 153(6): 1424-1431.
37. Zhou JS, Li ZY, Xu XC, et al. Cigarette smoke-initiated autoimmunity facilitates sensitisation to elastin-induced COPD-like pathologies in mice. Eur Respir J, 2020, 56(3): 2000404.
38. Liang Z, Wang F, Zhang D, et al. Sputum and serum autoantibody profiles and their clinical correlation patterns in COPD patients with and without eosinophilic airway inflammation. J Thorac Dis, 2020, 12(6): 3085-3100.
39. Costa S, Bevilacqua D, Cassatella M A, et al. Recent advances on the crosstalk between neutrophils and B or T lymphocytes. Immunology, 2019, 156(1): 23-32.
40. Martin KR, Pederzoli-Ribeil M, Pacreau E, et al. Transgenic mice expressing human proteinase 3 exhibit sustained neutrophil-associated peritonitis. J Immunol, 2017, 199(11): 3914-3924.
41. Wang F, Liang Z, Yang Y, et al. Sputum IgA autoantibodies predict the chronic obstructive pulmonary disease exacerbations. Am J Respir Crit Care Med, 2019(199): A4048.
42. Liang Z, Long F, Deng K, et al. Dissociation between airway and systemic autoantibody responses in chronic obstructive pulmonary disease. Ann Transl Med, 2020, 8(15): 918.
43. Stockley RA. Alpha-1 Antitrypsin Deficiency: Have we got the right proteinase? Chronic Obstr Pulm Dis, 2020, 7(3): 163-171.
44. Viglio S, Bak E G, Schouten I, et al. Protease-specific biomarkers to analyse protease inhibitors for emphysema associated with alpha 1-antitrypsin deficiency. An Overview of Current Approaches. Int J Mol Sci, 2021, 22(3): 1065.
45. Watz H, Nagelschmitz J, Kirsten A, et al. Safety and efficacy of the human neutrophil elastase inhibitor BAY 85-8501 for the treatment of non-cystic fibrosis bronchiectasis: a randomized controlled trial. Pulm Pharmacol Ther, 2019, 56: 86-93.
46. Griese M, Kappler M, Gaggar A, et al. Inhibition of airway proteases in cystic fibrosis lung disease. Eur Respir J, 2008, 32(3): 783-795.

Previous Article
代謝重編程在特發性肺纖維化中的研究進展

Chinese Journal of Respiratory and Critical Care Medicine

蛋白酶3在慢性阻塞性肺疾病中的研究進展

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Format

Content